Combined point mutation in KRAS or EGFR genes and EML4-ALK translocation in lung cancer patients

Future Oncology

Volumn 10, Issue 4, 2014, Pages 529-532

  Jürgens, Jessica ^a   Engel Riedel, Walburga ^a   Prickartz, Alexander ^a   Ludwig, Corinna ^a   Schildgen, Oliver ^a   Tillmann, Ramona Liza ^a   Stoelben, Erich ^a   Brockmann, Michael ^a   Schildgen, Verena ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

case series; lung cancer; mutation; novel combination; NSCLC

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; EML4-ALK FUSION PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADULT; AGED; ALGORITHM; ARTICLE; BONE METASTASIS; CANCER DIAGNOSIS; CANCER GENETICS; CASE REPORT; FATHER; FEMALE; GENE TRANSLOCATION; HUMAN; LUNG NON SMALL CELL CANCER; MALE; ONCOGENE K RAS; POINT MUTATION; PRIORITY JOURNAL; CARCINOMA, NON-SMALL-CELL LUNG; FATALITY; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FATAL OUTCOME; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 84899486092     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.194     Document Type: Article

References (15)

1. Felip E, Gridelli C, Baas P, Rosell R, Stahel R. Metastatic non-small-cell lung cancer. consensus on pathology and molecular tests, first-line, second-line, and third-line therapy. 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann. Oncol. 22(7), 1507-1519 (2011
2. Schildgen V, Lochi V, Lüsebrink J, Brockmann M, Schildgen O. Epidemiology of EML4-ALK translocations in a small, German non-small-cell lung cancer patient cohort. Pers. Med. 9(8), 801-803 (2012
3. Schildgen V, Schulz C, Lüsebrink J et al. Combination of Pyrosequencing' and Sanger sequencing reveals alleged novel mutation in exon 18 of EGFR. Pers. Med. 10(2), 201-209 (2013
4. Butrynski JE, D'Adamo DR, Hornick JL et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N. Engl. J. Med. 363(18), 1727-1733 (2010
5. Camidge DR, Doebele RC. Treating ALK-positive lung cancer - early successes and future challenges. Nat. Rev. Clin. Oncol. 9(5), 268-277 (2012
6. Chabner BA. Early accelerated approval for highly targeted cancer drugs. N. Engl. J. Med. 364(12), 1087-1089 (2011
7. Cheng H, Xu X, Costa DB, Powell CA, Halmos B. Molecular testing in lung cancer. The time is now. Curr. Oncol. Rep. 12(5), 335-348 (2010
8. Choi YL, Soda M, Yamashita Y et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363(18), 1734-1739 (2010
9. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363(18), 1693-1703 (2010
10. Mano H. Non-solid oncogenes in solid tumors. EML4-ALK fusion genes in lung cancer. Cancer Sci. 99(12), 2349-2355 (2008
11. Kim S, Kim TM, Kim DW et al. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J. Thorac. Oncol. 8(4), 415-422 (2013
12. Quest Diagnostics? - Mutation testing cascade for patients who are candidates for EGFR antagonist therapy. http://questdiagnostics.com/hcp/ intguide/ HematOnc/Gastrointestinal/TS-EGFR- Pathway.pdf
13. Aisner DL, Marshall CB. Molecular pathology of non-small cell lung cancer. A practical guide. Am. J. Clin. Pathol. 138(3), 332-346 (2012
14. Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer. implications for current and future therapies. J. Clin. Oncol. 31(8), 1039-1049 (2013
15. Sasaki T, Koivunen J, Ogino A et al A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 71(18), 6051-6060 (2011